New consultation: CRG actions May 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the May 2024 CRG meeting. Actions in this consultation include:

  • Levomepromazine 6.25mg tablets – green, alternative option where small doses are required and tablet splitting is not appropriate
  • Phenobarbital 15mg/5ml elixir – green (specialist advice) and grey (criterion 1), only for select adult patients for whom ethanol consumption is safe and appropriate. Not for use in children.
  • Bowl cleansing preparations – red, and product list updated to Plenvu, sodium picosulfate with magnesium citrate, and Klean-Prep
  • FreeStyle Libre 2 plus and Dexcom One plus – add as additional options for new and existing patients

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Friday 5th July 2024. To take part, visit the consultations page.


New consultation: communication standards for opioid medicines prescribed at discharge

On behalf of the GMMMG Medicines Safety Group, we now seek comments on draft Communication Standards for Opioid Medicines Prescribed at Discharge.

The draft document has been developed to support safe prescribing of opioids by improving and standardising the information communicated from secondary care to primary care when patients are discharged from hospital with an opioid medicine for pain management. The document has been developed by a task and finish group on behalf of the GM Medicines Safety Group. The document has been reviewed by members of the task and finish group, Medicines Safety Group, and has been circulated via the chief pharmacists group for comments.

This consultation will run for six weeks and closes at 5pm on Thursday 27th June 2024. To take part, visit the consultations page.


New consultation: CRG actions April 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the April 2024 CRG meeting. Actions in this consultation include:

  • Lamotrigine tablets – green specialist advice for bipolar disorder
  • Doxylamine / pyridoxine for nausea and vomiting in pregnancy – removed from grey list and made a first choice option alongside cyclizine and prochlorperazine
  • Levemir InnoLet and Insulatard InnoLet – remove from formulary following discontinuation of the products
  • Buprenorphine prolonged release solution for injection (Buvidal) – add to formulary as alternative to methadone and oral buprenorphine
  • Fluocinolone intravitreal implant – RED
  • Dupilumab for prurigo nodularis – DNP
  • Etrasimod for ulcerative colitis – RED
  • Ritlecitinib for alopecia areata – RED
  • Satralizumab for neuromyelitis optica spectrum disorders – DNP
  • Sebelipase alfa for lysosomal acid lipase deficiency – DNP

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Friday 24th May 2024. To take part, visit the consultations page.


New consultation: CRG actions March 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the March 2024 CRG meeting. Actions in this consultation include:

  • Doxazosin 8mg immediate-release tablets – DNP
  • Atropine 1% eye drops and minims for hypersalivation – GREEN (following specialist advice)
  • Paliperidone palmitate 700mg & 1000mg prolonged-release suspension for injection – add to formulary as AMBER (see also separate consultation on updated shared care protocol)
  • Add belumosudil as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Thursday 28th March 2024. To take part, visit the consultations page.


New consultations: asthma, tobacco, and paliperidone

Three new consultations have opened on the GMMMG website:

  • Asthma Guideline – update for 2024, to include AIR therapy
  • Medical Management of Tobacco Dependency guidelines – update for 2024, to include cytisine
  • Shared care protocol for paliperidone long-acting injection – update

All three consultations will run for six weeks, and close at 5pm on Wednesday 24th April. To take part in these or any other consultations, visit https://gmmmg.nhs.uk/consultations/.


New consultation: CRG actions February 2024

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their February 2024 meeting. Actions in this consultation include:

  • Riluzole 50mg orodispersible tablets added as AMBER
  • Diclofenac 50mg tablets made 3rd line choice, after ibuprofen and naproxen
  • Sebeliplase alfa added as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

This consultation will run for six weeks and closes at 5pm on Thursday 28th March 2024. To take part, visit the consultations page.


Consultation: GM non-medical prescriber best practice guide

Following development by the GM NMP Leads Group and review by the GM Workforce Group, we now seek comments on the draft document: ‘Greater Manchester Non-Medical Prescribing Best Practice Guide’.

The consultation will run for six weeks and closes at 5pm on Thursday 2nd November 2023. To take part, visit the consultations page.


Consultation: actions from September 2023 CRG meeting

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their September 2023 meeting. Actions in this consultation include:

  • Tadalafil 5mg once daily – remove from DNP list and assign GREEN RAG status
  • Herbal treatments – DNP listing amended to “herbal treatments and other natural products”, in line with NHS England guidance
  • Cipaglucosidase alfa – add to formulary as RED

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Friday 27th October 2023. To take part, visit the consultations page.


Consultation: actions from August 2023 CRG meeting

On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at their August 2023 meeting. Actions in this consultation include:

  • Sodium chloride 5% eye drops – RED
  • Bempedoic acid – comments sought regarding a change to GREEN
  • Steroid eye drops (betamethasone 0.1%, dexamethasone 0.1%, prednisolone 0.03%, 0.1%, 0.5% & 1%, fluorometholone 0.1%) – GREEN (specialist initiation)
  • Rimegepant for preventing migraine – GREEN (specialist initiation) OR GREEN (specialist advice)
  • Semaglutide for overweight and obesity in young people aged 12-17 years – Do Not Prescribe.

All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.

The consultation will run for six weeks and closes at 5pm on Friday 22nd September 2023. To take part, visit the consultations page.


Consultation: updated HCD inflammatory bowel disease pathway

Following development by a clinical working group and review by CRG, we now seek comments on the draft update of the GMMMG High Cost Drugs Inflammatory Bowel Disease Pathway.

The consultation will run for 6 weeks, closing at 5pm on 30th August. To take part, please visit the consultations page.